Pharma BD Deal Intelligence
Merck & Co. Inc. / Kelun-Biotech Biopharmaceuticals Co. Ltd.
2022 · Licensing/Option · $936M · Complete
Announcement Sentiment
83
Strongly positive
Outcome Score
60
Largely worked — most objectives met.
Merck licensed a second ADC candidate from Kelun-Biotech for solid tumor treatment, the second of three ADC deals in 2022.
Key facts
- Announced Jul 15, 2022
- Closed Jul 15, 2022
- Deal value $936M
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications Solid tumors
- Key assets Undisclosed ADC
- Mechanism Antibody-drug conjugate
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals